Erythroderma may be secondary to a cutaneous T-cell lymphoma (CTCL) and various other erythrodermic inflammatory dermatoses (EID), and their histopathologic distinction is often difficult. The aim of this study was to determine if morphological parameters, namely: the presence of b-catenin, and JunB (previously shown to be expressed by CTCL cells), the epidermal CD8:CD3 ratio, and CD30 expression may help in the histopathologic diagnosis of erythroderma, especially in differentiating CTCL and EID. We retrospectively reviewed a series of 47 skin biopsies from patients with erythroderma (18 CTCL and 29 EID). The diagnosis of each case was established using clinical, biological and histopathologic data. After a blind assessment of the hematoxylin-eosin-safran stained slides, a correct diagnosis of the underlying cause of erythroderma was made only in 31% of cases. A correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Various morphologic and phenotypic parameters were then recorded and we compared their frequency in the CTCL versus the EID group. With the exception of atypical lymphocytes, the moderate to high density of dermal infiltrates and Pautrier microabcesses, only found in CTCL, no morphologic parameter was found to be specific of CTCL, although single lymphocytes epidermotropism, telangiectasias, and slight lymphocytic dermal infiltrate were significantly more frequent in EID. A low (,10%) CD8:CD3 ratio in the epidermal lymphocytic infiltrate and dermal CD30+ lymphocytes were significantly more frequent in CTCL. JunB expression by lymphocytes was specific of CTCL, but was inconstant in our series (17%). We found b-catenin expression in a minority of cases from both the CTCL and EID groups. Among EID, dermal suprapapillary thinning was specific of psoriasis. Neutrophils exocytosis and edema of papillary dermis were significantly more frequent in psoriasis, and spongiosis was more frequent in eczema. In conclusion, few morphological and phenotypical parameters are helpful in making a differential diagnosis between erythrodermic CTCL and EID using paraffin embedded skin biopsies.
INTRODUCTION
Erythroderma may result from several causes, including cutaneous T-cell lymphomas (CTCL), especially Sézary syndrome (SS), and several erythrodermic inflammatory diseases (EID), mostly psoriasis, drug eruptions or atopic dermatitis. 1 It is difficult to establish the underlying cause in practice, since clinical and histological aspects are not specific. Especially, it is necessary to differentiate EID from SS, which is an aggressive lymphoma and requires an early and appropriate management. 2 Erythroderma can present with a large variety of histologic patterns. However, there have been only few series detailing the histologic features of erythroderma. The identification of a monoclonal T-cell population has been proved to be of high value for the diagnosis of CTCL, [3] [4] [5] [6] [7] but is not fully specific, unless a similar T-cell clone is found in the blood and skin. 8 New markers of SS have been described in the past 10 years using flow cytometry studies on circulating CD4 + T cells (loss of CD26, CD7, and CD49d), [9] [10] [11] [12] and molecular studies in sorted circulating T cells or skin samples (Twist, EphA4, and T-plastin). 13, 14 Notably, CD158k/KIR3DL2 was shown to be highly specific for malignant CD4 + T cells, allowing diagnosis of SS in the blood using flow cytometry and in the skin using reverse transcription polymerase chain reaction. [15] [16] [17] Among new markers of SS, only b-catenin and JunB have been shown to be suitable for immunohistochemistry on paraffin-embedded skin biopsies. Beta-catenin is a ubiquitously cytoplasmic protein that acts as a component of the homotypic cell-cell adhesion apparatus. It is also a critical member of the Wnt signaling pathway, which plays an important role in embryonic development and tumorigenesis. [18] [19] [20] [21] Interestingly, a recent study has shown that b-catenin is expressed in high grade CTCL. 22 Indeed, immunohistochemical analysis demonstrated b-catenin expression in a majority of SS samples (70%) and in a proportion of mycosis fungoides. JunB is a member of the Jun family of proteins that are components of the activator protein 1 (AP-1) transcription factor complex. AP-1 members are involved in cell proliferation and apoptosis, thus contributing to oncogenesis. 23 Recent studies have shown that JunB is expressed in various lymphomas, especially systemic and cutaneous CD30 + lymphomas, including lymphomatoid papulosis and cutaneous anaplastic T-cell lymphoma. 24 In addition, in a recent study, amplification of the JunB gene was found in lymphocytes from patients with SS and mycosis fungoides (MF), and immunohistochemical analysis showed nuclear expression of JunB in the majority of SS (91%) and MF (50%) samples. 25 This suggested that JunB may help to make a differential diagnosis between SS and EID in routine practice. We therefore conducted a retrospective study to determine whether morphologic parameters, lymphocyte phenotyping, including the epidermal CD8:CD3 ratio, CD30, and the recently described markers b-catenin and JunB may help for the diagnosis of erythroderma with paraffinembedded skin biopsies, especially to make a differential diagnosis between CTCL and EID.
MATERIALS AND METHODS

Patients and Material Selection
We retrospectively included 47 biopsies specimens from the 45 adult patients who presented in the Department of Dermatology of our institution with a clinical diagnosis of erythroderma between September 1996 and November 2007. There were 28 men and 17 women, with a median age of 70 years (range 36-96 years). In each case, the final etiological diagnosis of erythroderma was established according to all the clinical, biological, morphological, and immunohistochemical data obtained previously to the study, including T-cell clonality results and CD158k/KIR3DL2, shown to be a marker of SS in circulating CD4 + T cells 16, 26 and in erythrodermic skin. 17 Final diagnoses were CTCL in 18 patients, including 14 SS, 3 erythrodermic MF, and 1 secondary cutaneous lymphoma. Twenty-nine patients had a benign erythrodermic inflammatory dermatosis (EID): drug eruption (n = 5), psoriasis (n = 9), eczema (n = 5). The remaining patients (n = 10) had pityriasis rubra pilaris, myelodysplastic syndrome, dermatomyositis, irritative dermatitis, or idiopathic erythroderma (n = 6).
Histopathology and Immunohistochemistry: Techniques and Parameters Analyzed
Hematoxylin-eosin-safran (HES) stained slides and formalin-fixed, paraffin-embedded blocks were retrieved from the archive material of our Department of Pathology.
Immunohistochemistry was applied to 3-mm-thick sections, using monoclonal antibodies to CD3, CD8, CD30 (Dako, SA), and JunB (C-11, Santa-Cruz biotechnology, 1:50) and b-catenin (CAT 5H10, Zymed Laboratories, 1:100). We used a standard avidin-biotin-peroxidase method with diaminobenzidine chromogen, using the Nexes immunostainer (Ventana, Tucson AZ), after antigen retrieval by heat in the appropriate buffer. Immunostaining of b-catenin was done manually with the horseradish peroxidase method and revealed by aminoethylcarbazole. Briefly, 3-mm sections were deparaffinized in xylene for 30 minutes and rehydrated through graded ethanol. Sections were first heated at 98°C for 30 minutes in a citrate buffer solution to retrieve the antigen. Endogenous peroxidase activity was blocked for 15 minutes with 3% hydrogen peroxidase. Nonspecific antibody binding was blocked for 10 minutes by incubation with protein block serum free (Vector laboratories, vectastain universal, ABC KIT). After a series of washes, the sections were incubated with primary mouse monoclonal antibody at room temperature in a humidity chamber for 2 hours. The primary antibody was visualized using an anti-mouse horseradish peroxidase system with aminoethylcarbazole as the chromogen. Sections were then counterstained by hematoxylin. Positive immunoreactivity of keratinocytes was used as an internal positive control for both b-catenin at the cell membrane 22 and JunB in the nuclei. 25 The immunostaining of JunB was considered to be positive when it was at least as positive as suprabasal keratinocytes. In addition, as controls, we analyzed JunB immunostaining in a series of CD30 + lymphomas, retrieved from the archive material of our Department of Pathology, which are all expected to be positive for JunB expression, according to the results obtained by Rassidakis et al. 24 All HES slides were reviewed in a blind fashion by 2 dermatopathologists (C.R. and N.O.). First, a global assessment of each HES-stained slide was made, and a diagnosis based on the histopathology alone was done. The morphologic aspects were considered to be either characteristic for one diagnostic, for several diagnostic or nonspecific. Then the following morphologic parameters were systematically recorded, according to precedent studies that focused on the histopathologic aspects of CTCL or erythroderma. [27] [28] [29] [30] [31] Immunohistochemical parameters analyzed were as follows: the presence of CD30 + , b-catenin + , and JunB + lymphocytes in both the dermis and epidermis were recorded. The density of positive cells was categorized as low (0%-10% positive lymphocytes), intermediate (.10%-50%), or strong (.50%-100%). The epidermal CD8:CD3 ratios were evaluated in all cases. A semiquantitative analysis was done, in which we categorized these ratios into 3 groups: 1 (0%-10%), 2 (.10%-50%), 3 (.50%-100%).
Statistical Analysis
Statistical correlations used the Chi-squared test and the Mann-Whitney U-test (Statview, abacus concept). We first compared the CTCL and the EID groups. Each morphologic and immunohistochemistry parameter was studied. Then, we evaluated the morphologic parameters that are usually considered to be of diagnostic value in the histopathologic diagnosis of psoriasis, eczema, and drug eruption to determine whether they may be useful in the context of erythroderma. Differences were considered to be statistically significant at P , 0.05.
RESULTS
Comparison of the Diagnoses Made With Histopathology Alone With the Final Diagnosis
Comparison of the diagnoses based on pathologic findings with the final diagnoses revealed that a correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Two patients with a benign form of erythroderma showed a histologic picture that suggested CTCL, because of a suspect epidermotropism. Considering all etiological diagnoses, skin biopsy analysis alone yielded a correct diagnosis in 31% of cases and a nonspecific aspect in 27%. In the remaining cases, the final diagnosis was only suspected (20/47, 42%). Diagnosis of CTCL was more easy (61% of certain diagnosis) than diagnosis of EID. In the EID group, the aspect was actually considered non specific in 41% of cases, and the correct diagnosis was only suspected among other diagnoses in 45% of cases.
Comparison of Erythrodermic Lymphoma With Inflammatory Dermatoses
Results of the morphologic study are summarized in Table 1 and Figure 1 . Results of immunohistochemistry are summarized in Table 2 and Figure 2 .
We compared the CTCL and the EID groups for each morphological parameter recorded. The presence of Pautrier microabcesses (44%, P = 0.004), atypical lymphocytes (66%, P = 0.014), a high (28%, P = 0.011), or intermediate (67%,P = 0.036) density lymphocytic infiltrate were significantly associated with diagnosis of CTCL. Pautrier microabcesses (Fig. 1C) , atypical lymphocytes, and a dense dermal infiltrate were found only in CTCL (Fig. 1E ). In addition, in one case of CTCL we observed presence of basilar lymphocytes, a feature that was never found in any EID sample. Fibrosis of papillary dermis and lymphocyte epidermotropism were not significantly associated with diagnosis of erythrodermic CTCL. By contrast, single lymphocytes epidermotropism (P = 0.006), a low density lymphocytic dermal infiltrate (P , 0.0001) and telangiectasias (P = 0.015) were significantly more frequent in EID.
Regarding immunohistochemical parameters, an epidermal CD8:CD3 ratio ,10% was seen in most CTCL (56% versus 21% in EID, P = 0.032). In all cases, the density of JunB + , b-catenin + , and CD30 + lymphocytes was low (,10% of lymphocytes). CD30 + lymphocytes, when present, were found in the dermal infiltrates. CD30 expression was not discriminant between CTCL and EID but was significantly more frequent in CTCL (14/18, 78% versus 11/29, 38% in EID, P = 0.009; Fig. 2A, B) . Interestingly, a proportion of CD30 + lymphocytes in CTCL were morphologically atypical, suggesting that at least a proportion of positive cells were neoplastic ( Fig. 2A) . b-Catenin expression in lymphocytes was rare and when positive, it was inconspicuous, mainly found in the cytoplasm and heterogeneous within the dermal infiltrates. b-Catenin positivity was not discriminant (P . 0.999) between CTCL (5/18, 28%) and EID (9/29, 31%). Using a double immunostaining with CD3 (red), we confirmed that b-catenin-positive cells (brown) within the infiltrate were T lymphocytes (Fig. 2F ). JunB expression was found only in CTCL cases but with a very low sensitivity in this series with only 3 positive cases (17% of CTCL, P = 0.049). Interestingly we noticed a heterogeneous expression within the neoplastic cells, even in a single Pautrier microabcess (Fig. 2C, inset) . In 2 of the 3 JunB + CTCL cases, CD30 was also expressed. In addition, we noticed that the 3 JunB + cases were actually diagnosed as cutaneous lymphomas using morphology alone, showing either Pautrier microabcesses and/or atypical lymphocytes.
Analysis of the Subgroups of Inflammatory Dermatose: Psoriasis, Eczema, and Drug Eruptions
We then considered separately the subgroups of EID, including psoriasis, eczema, and drug eruption. Suprapapillary thinning was an inconstant finding but was found only in psoriasis (2/9, 22%, P = 0.038). Exocytosis of neutrophils was significantly associated with a diagnosis of psoriasis (78% versus 18% of other erythroderma, P = 0.006), and subcorneal pustules (67% versus 13%, P = 0.003; Fig. 1D ) and edema of papillary dermis (P = 0.044). Psoriasiform hyperplasia was frequently observed but not significantly associated with psoriasic erythroderma (P = 0.129). Similarly, the number of mitoses per mm was not increased in erythrodermic psoriasis as compared with other groups (P = 0.059). Marked and confluent spongiosis (prevesicles) was significantly associated with eczema (60% versus 5% of other erythroderma, P = 0.002; Fig. 1F) , whereas constituted vesicles seemed to be rare. Parakeratosis (P = 0.365), edema of papillary dermis (P = 0.714), irregular hyperplasia (P . 0.999), and single lymphocyte epidermotropism (P = 0.888) were frequently observed but not significantly associated with eczematous erythroderma. Pagetoid epidermotropism seemed pathognomonic of eczematous erythroderma (2/5, 40%). Unexpectedly, the total number of apoptotic keratinocytes was not significantly increased in erythrodermic drug reactions (0.07 apoptotic bodies per mm versus 0.26 in other causes, P = 0.719; Table 1 ). Focal interface dermatitis (P . 0.999) and eosinophils in dermal infiltrate were not significantly associated with drug-induced erythroderma.
DISCUSSION
One of the most important challenges facing a dermatopathologist when evaluating skin biopsies from erythrodermic patients lies in the distinction between benign and malignant causes. Previous studies have already highlighted the difficulties for making a definitive diagnosis with paraffin embedded skin biopsies in this context. 28, 29, 31, 32 In the past 10 years, new phenotypic and molecular markers of malignant Sézary cells were published, including loss of CD26 and CD7, expression of Twist, EphA4, T-plastin, and CD158k/KIR3DL2, the latter allowing diagnosis in skin biopsies with quantitative reverse transcription polymerase chain reaction. [15] [16] [17] In addition, among the new markers, only b-catenin and JunB have been proved to be suitable for immunohistochemistry on paraffin-embedded skin biopsies, 22, 25 but there has been no additional study to date that evaluated these markers in a series of erythroderma.
Our findings indicate that the diagnosis of the underlying cause of erythroderma was made (31%) or suspected (42%) by histopathologic examination in only 73% of cases, when microscopic patterns more or less reproduced those seen in conventional manifestations of the underlying diseases. Those results are in keeping with precedent studies (Table 3) supporting the view that skin biopsy is a useful procedure in the evaluation of patients with erythroderma, but remains insufficient to make a correct diagnosis in all instances. According to a previous study from Walsh et al, 32 morphologic identification of CTCL, psoriasis, and spongiotic dermatitis as underlying causes of erythroderma was more successful than that of drug eruption or other causes. In the present study, the diagnosis of CTCL was more easily confirmed by conventional microscopy alone (61% of certitude of the diagnosis in this group). In Table 3 , we reported main results from this study and previous publications on the diagnosis of erythroderma with skin biopsy.
In previous morphological studies, Zip et al 29 and Sentis et al 33 reported that when Pautrier microabcesses are present, a diagnosis of CTCL can be rendered with certainty. In our study, the presence of atypical dermal lymphocytes and a moderate to dense dermal lymphocytic infiltrate were also more frequently observed in CTCL. As for Pautrier microabcesses sometimes they may be absent. Similarly, only one case of CTCL showed basilar lymphocytes (lymphocytes aligned within the basal layer). This is in agreement with Kohler et al who reported that this feature was more frequent in limited patch/plaque lesions of MF than in erythrodermic CTCL. 31 In addition, we show that the identification of numerous dilated vessels favors a diagnosis of EID.
Bellei et al demonstrated b-catenin expression in 31% of MF and 70% of SS samples using immunohistochemistry. In this study, none of the 10 investigated inflammatory dermatitis expressed b-catenin, suggesting that this marker is specific for CTCL diagnosis. 22 In our study, we found that b-catenin expression was rare and not discriminant between CTCL (5/18, 28%) and EID (9/29, 31%), and was actually seen in T cells, according to double immunohistochemistry results in representative samples. Similarly, CD30 expression was not discriminant between CTCL and EID, although the finding of CD30 + lymphocytes was significantly more frequent in CTCL. It is already documented that CD30 + lymphocytes can be found in reactional lymphocytic infiltrates. In addition, as shown in a recent study, CD30 + lymphocytes in reactional condition can be large cells, simulating atypical lymphocytes of CTCL. 34 Such findings further suggest that CD30 is of limited value in making a diagnosis of CTCL. Interestingly, according to Bellei et al, the deregulation of b-catenin seems to correlate with CD30 expression. 22 In our study, it is noticeable that all CTCL positive for b-catenin also comprised CD30 + lymphocytes. The expression of CD30 can be induced on normal blood B and T cells by mitogens and viruses, indicating that CD30 is associated with activation of lymphoid cells. The positivity of b-catenin in minor T-cell subsets in erythroderma might therefore correlate with the presence of activated T-cells, which is expected in both inflammatory and lymphomatous erythroderma. Sézary cells indeed are neoplastic-activated helper T-cells. 22 Importantly, the possible activation of the classical Wnt pathway in normal T-cells, with b-catenin expression, has already been mentioned in the literature, at least in the CD8 + subset. 35 In the present study, JunB expression was specific of CTCL but with a very low sensitivity (17% of CTCL) and with a very heterogeneous pattern among atypical lymphocytes. Such results are contrasting with previous studies in which JunB expression was mentioned in up to 91% of SS and 50% of MF. 25 Interestingly, in 2 of the 3 JunB + CTCL cases, we noticed that CD30 was also expressed. This result may suggest that JunB and CD30 expression in these CTCL are linked, such as in Reed-Sternberg cells in Hodgkin lymphoma, in which CD30 expression was shown to be induced by JunB through an interaction with the CD30 gene promoter. 24, 36 The discordance between our results and results obtained previously is difficult to explain. Such discordance has recently been found regarding the NAV3 deletion gene, shown to be a specific marker of MF and SS neoplastic cells 37 and later found to be rather a rare and nonspecific event. 38 Multicentric and comparative studies on larger series of cases are thus needed to better evaluate the real sensitivity and specificity of these markers.
In conclusion, characterization of erythroderma in skin biopsies is difficult morphologically, so that a definite diagnosis can be rendered in only a proportion of cases, one-third in the present study. Only few histopathologic features allow characterization of the underlying etiology, which are Pautrier microabcesses, atypical lymphocytes with hyperconvoluted nuclei, and a dense dermal infiltrate for CTCL. Among new markers of CTCL, JunB is not a sensitive feature but is specific for CTCL, whereas in this study, b-catenin expression was rare and inconspicuous in lymphocytes, and did not allow differential diagnosis between CTCL and erythrodermic inflammatory dermatoses. In light of these results, the search for new specific markers working in paraffinembedded tissue sections needs to be continued to improve the diagnostic value of skin biopsy in erythroderma. 
